I had a patient with NHL and who was being treated with R-CHOP. A few weeks later, the patient was reviewed at the Haem'o'hell (Haematology) MDT which I was attending. Anyway, it transpired that the patient did not have CD20+ B-cells. The Rituximab was not going to be beneficial to the patient, it was against NICE guidance and was costing lots of money. We did a bigger review of the patients on R-CHOP and found that this was not an isolated case, the haematologists were just adding in the Rituximab because they felt it was beneficial. We stopped this excessive prescribing of Rituximab and saved lots and lots and lots and lots of money for the tax payers
Was this the kind of thing you were after???
Here are some links to help:
NHL NICE guidance NHL - Rituximab 
_RoB_